CD22 and precursor B-cell acute lymphoblastic leukemia: Another phase I clinical trial conducted by Shalabi et al. reported that 10 out of 20 patients treated with CD19/CD22 bivalent CAR T cells to treat B-ALL in children and adults experienced CRS, with 3 having grade 3 CRS [65].